According to recent research, prior β-blocker usage is related to prolonged time-to-discontinuation (TTD) and survival rates (OS) in treatment-naive patients who have advanced lung cancer following first-line EGFR-TKIs67. The gene discussed is EGFR; the disease is lung cancer.